CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rated Strong-Buy in New Coverage at Raymond James Financial

Raymond James Financial began coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a report released on Friday morning, Marketbeat.com reports. The firm issued a strong-buy rating and a $10.00 target price on the Wireless communications provider’s stock.

Several other equities analysts have also recently commented on CAMP. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Piper Sandler restated an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Wall Street Zen downgraded shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Needham & Company LLC initiated coverage on shares of CAMP4 Therapeutics in a report on Thursday, October 15th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Oppenheimer initiated coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They issued an “outperform” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $10.44.

CAMP4 Therapeutics Price Performance

Shares of CAMP opened at $3.30 on Friday. The company has a market capitalization of $207.07 million, a price-to-earnings ratio of -1.42 and a beta of 0.27. CAMP4 Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $7.75. The business’s 50-day moving average is $3.99 and its 200-day moving average is $4.13.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Equities research analysts expect that CAMP4 Therapeutics will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling at CAMP4 Therapeutics

In related news, Director Richard Young acquired 16,378 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares of the company’s stock, valued at $307,540.20. The trade was a 9.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kelly Gold acquired 10,000 shares of the business’s stock in a transaction on Monday, August 31st. The shares were bought at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. Company insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the 2nd quarter valued at $78,000. Trails Edge Capital Partners LP acquired a new position in CAMP4 Therapeutics in the second quarter worth $8,446,935. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics in the second quarter worth $27,581,000. 5AM Venture Management LLC acquired a new position in CAMP4 Therapeutics in the second quarter worth $25,647,928. Finally, BlackRock Inc. acquired a new position in CAMP4 Therapeutics in the second quarter worth $7,185,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.